Palvella Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Palvella Therapeutics (PVLA).

Price Target Range — 9 Quarters

Analyst Consensus — 17 Analysts

1S.Buy

16Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$164Upside to Avg. PT+11.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	Chardan Capital	Gautam Chukka	Maintained	Buy	$240
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 12, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Cut	Buy	$270→$246
Sep 21, 2026	Chardan Capital	Gautam Chukka	Maintained	Buy	$240
May 21, 2026	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$220
May 21, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$240
May 12, 2026	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$220
Mar 31, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$210→$240
Mar 24, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$255→$270
Mar 16, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$210
Feb 25, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$205→$250
Feb 25, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$192→$215
Feb 24, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$174→$210
Feb 24, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$200→$255
Jan 29, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$192
Jan 16, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$192
Jan 7, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$205
Dec 16, 2025	Truist Securities	Danielle Brill	PT Raise	Buy	$105→$190
Dec 16, 2025	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$148→$204
Dec 16, 2025	TD Cowen	Ritu Baral	PT Raise	Buy	$97→$133

Analyst Ratings News

PRO
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.

Benzinga Newsdesk

Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday

Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.

Benzinga Newsdesk

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.

Benzinga Newsdesk

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Overweight rating and announces Price Target of $220.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.

Benzinga Newsdesk

Palvella Therapeutics Inc

Palvella Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

People Also Watch

People Also Watch

Palvella Therapeutics Inc

Palvella Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWilliam Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday

PROHC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

PROStephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

PROStephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

PROChardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

People Also Watch

People Also Watch

PRO
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

PRO
Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

PRO
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240